Toggle search Open search menu icon SEARCH THE SITE Open contact page icon Contact Parking icon Find & Parking
Royal Devon and Exeter NHS logo

Research Trials at Exeter


Please select the dropdowns below to find details of upcoming, ongoing, and completed research trials in Exeter.

Study Title: CF Start

Status: Open and recruiting until January 2020

What is the study investigating? To compare two treatment strategies, “Prevent and Treat” flucloxacillin prophylaxis in babies with CF (standard care in the UK) vs “Detect and Treat” antibiotics prescribed depending on swab results.

Who can take part? Babies with CF less than 70 days old

What does it involve? A computer system will be used to choose whether the baby begins on prophylactic flucloxacillin treatment, or receives targeted antibiotics depending on the results of their cough swabs. There won’t be any extra hospital visits but the child’s progress will be followed closely for 48 months

More info can be found at http://www.cfstart.org.uk/

Co-Investigators: Dr Beth Enderby and Dr Patrick Oades

Contact: Sophie Whiteley s.whiteley1@nhs.net

These are studies that have finished recruiting new patients, but are still being worked on in Exeter to collect the results for the study, or recently completed studies. If you have any questions about these studies please direct them to Sophie at s.whiteley1@nhs.net

 

Study Title:  ACTIF – Development and evaluation of an intervention to support adherence to treatment in adults with Cystic Fibrosis

Status – Closed to recruitment, follow up ongoing

What is the study investigating? Does the CFHealthHub intervention increase adherence to nebulised medications?

Results – Awaited

 

Study Title: Vertex 106 and 108

Status – Completed

What is the study investigating? The safety and effectiveness of VX-661 (now known as Tezacaftor) and Ivacaftor vs placebo in people with CF aged 12years+ who are homozygous F508 (Vertex 106 study) and who have one copy of F508 and one residual function variant (Vertex 108)

Results – Tez/Iva was shown to increase lung function (FEV1) in participants and reduce the rate of exacerbations when compared to placebo.

More in depth results can be accessed here for Vertex 106 and Vertex 108.

This combination is being marketed as “Symkevi” in the UK, but a reimbursement deal has not yet been agreed

 

Study title – Vertex 110

Status – Closed to recruitment, follow up ongoing

What is the study investigating? Long term safety and effectiveness of Tez/Iva in subjects who took part in Vertex 106/108 over 96 weeks

Results – Awaited

 

Study title: Vertex NextGen programme

Status: Closed to recruitment, follow up ongoing

What is the study investigating? The long term safety and effectiveness of Tezacaftor, Ivacaftor and VX-445 (Triple therapy) in people with CF aged 12years+ firstly for either 4 or 24 weeks vs placebo, then over 96 weeks

Results – Full results not yet available but topline results have been released as a press release here

VX-445 has been named Elexacaftor and the triple therapy combination is being submitted for licensing in the US and in Europe later in 2019

 

Study title:  Hope-1 – Hydration for Optimal Pulmonary Effectiveness

Status: Complete

What is the study investigating? The effect of inhaled treatment SPX-101 over 4 weeks

Results: Awaited

Section to be coming soon